136 related articles for article (PubMed ID: 37562004)
1. CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma.
Decombis S; Bellanger C; Le Bris Y; Madiot C; Jardine J; Santos JC; Boulet D; Dousset C; Menard A; Kervoelen C; Douillard E; Moreau P; Minvielle S; Moreau-Aubry A; Tessoulin B; Roue G; Bidère N; Le Gouill S; Pellat-Deceunynck C; Chiron D
Blood; 2023 Nov; 142(18):1543-1555. PubMed ID: 37562004
[TBL] [Abstract][Full Text] [Related]
2. Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation.
Knies N; Alankus B; Weilemann A; Tzankov A; Brunner K; Ruff T; Kremer M; Keller UB; Lenz G; Ruland J
Proc Natl Acad Sci U S A; 2015 Dec; 112(52):E7230-8. PubMed ID: 26668357
[TBL] [Abstract][Full Text] [Related]
3. Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.
Wu C; de Miranda NF; Chen L; Wasik AM; Mansouri L; Jurczak W; Galazka K; Dlugosz-Danecka M; Machaczka M; Zhang H; Peng R; Morin RD; Rosenquist R; Sander B; Pan-Hammarström Q
Oncotarget; 2016 Jun; 7(25):38180-38190. PubMed ID: 27224912
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
[TBL] [Abstract][Full Text] [Related]
5. Gain-of-function mutations in CARD11 promote enhanced aggregation and idiosyncratic signalosome assembly.
Stinson JR; Dorjbal B; McDaniel DP; David L; Wu H; Snow AL
Cell Immunol; 2020 Jul; 353():104129. PubMed ID: 32473470
[TBL] [Abstract][Full Text] [Related]
6. Synergistic activity of Card11 mutant and Bcl6 in the development of diffuse large B-cell lymphoma in a mouse model.
Takahara T; Matsuo K; Seto M; Nakamura S; Tsuzuki S
Cancer Sci; 2016 Nov; 107(11):1572-1580. PubMed ID: 27560392
[TBL] [Abstract][Full Text] [Related]
7. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Davis RE; Ngo VN; Lenz G; Tolar P; Young RM; Romesser PB; Kohlhammer H; Lamy L; Zhao H; Yang Y; Xu W; Shaffer AL; Wright G; Xiao W; Powell J; Jiang JK; Thomas CJ; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Johnson NA; Rimsza LM; Campo E; Jaffe ES; Wilson WH; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pierce SK; Staudt LM
Nature; 2010 Jan; 463(7277):88-92. PubMed ID: 20054396
[TBL] [Abstract][Full Text] [Related]
8. Intramolecular Interactions and Regulation of Cofactor Binding by the Four Repressive Elements in the Caspase Recruitment Domain-containing Protein 11 (CARD11) Inhibitory Domain.
Jattani RP; Tritapoe JM; Pomerantz JL
J Biol Chem; 2016 Apr; 291(16):8338-48. PubMed ID: 26884334
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.
Bognar MK; Vincendeau M; Erdmann T; Seeholzer T; Grau M; Linnemann JR; Ruland J; Scheel CH; Lenz P; Ott G; Lenz G; Hauck SM; Krappmann D
Oncogene; 2016 Aug; 35(32):4269-81. PubMed ID: 26776161
[TBL] [Abstract][Full Text] [Related]
10. Cooperative Control of Caspase Recruitment Domain-containing Protein 11 (CARD11) Signaling by an Unusual Array of Redundant Repressive Elements.
Jattani RP; Tritapoe JM; Pomerantz JL
J Biol Chem; 2016 Apr; 291(16):8324-36. PubMed ID: 26884335
[TBL] [Abstract][Full Text] [Related]
11. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
[No Abstract] [Full Text] [Related]
12. MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.
Aggarwal V; Das A; Bal A; Srinivasan R; Das R; Prakash G; Malhotra P; Varma S
Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):311-318. PubMed ID: 29734251
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic understanding of the combined immunodeficiency in complete human CARD11 deficiency.
Lu HY; Sharma M; Sharma AA; Lacson A; Szpurko A; Luider J; Dharmani-Khan P; Shameli A; Bell PA; Guilcher GMT; Lewis VA; Vasquez MR; Desai S; McGonigle L; Murguia-Favela L; Wright NAM; Sergi C; Wine E; Overall CM; Suresh S; Turvey SE
J Allergy Clin Immunol; 2021 Dec; 148(6):1559-1574.e13. PubMed ID: 33872653
[TBL] [Abstract][Full Text] [Related]
14. Molecular Determinants of Scaffold-induced Linear Ubiquitinylation of B Cell Lymphoma/Leukemia 10 (Bcl10) during T Cell Receptor and Oncogenic Caspase Recruitment Domain-containing Protein 11 (CARD11) Signaling.
Yang YK; Yang C; Chan W; Wang Z; Deibel KE; Pomerantz JL
J Biol Chem; 2016 Dec; 291(50):25921-25936. PubMed ID: 27777308
[TBL] [Abstract][Full Text] [Related]
15. Role of nuclear factor-κB regulators TNFAIP3 and CARD11 in Middle Eastern diffuse large B-cell lymphoma.
Bu R; Bavi P; Abubaker J; Jehan Z; Al-Haqawi W; Ajarim D; Al-Dayel F; Uddin S; Al-Kuraya KS
Leuk Lymphoma; 2012 Oct; 53(10):1971-7. PubMed ID: 22397314
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase.
Steinhardt JJ; Peroutka RJ; Mazan-Mamczarz K; Chen Q; Houng S; Robles C; Barth RN; DuBose J; Bruns B; Tesoriero R; Stein D; Fang R; Hanna N; Pasley J; Rodriguez C; Kligman MD; Bradley M; Rabin J; Shackelford S; Dai B; Landon AL; Scalea T; Livak F; Gartenhaus RB
Blood; 2014 Dec; 124(25):3758-67. PubMed ID: 25320244
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.
Lenz G; Davis RE; Ngo VN; Lam L; George TC; Wright GW; Dave SS; Zhao H; Xu W; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Chan WC; Staudt LM
Science; 2008 Mar; 319(5870):1676-9. PubMed ID: 18323416
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathways: targeting MALT1 paracaspase activity in lymphoma.
Fontán L; Melnick A
Clin Cancer Res; 2013 Dec; 19(24):6662-8. PubMed ID: 24004675
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells.
Ferch U; Kloo B; Gewies A; Pfänder V; Düwel M; Peschel C; Krappmann D; Ruland J
J Exp Med; 2009 Oct; 206(11):2313-20. PubMed ID: 19841089
[TBL] [Abstract][Full Text] [Related]
20. A quantitative signaling screen identifies CARD11 mutations in the CARD and LATCH domains that induce Bcl10 ubiquitination and human lymphoma cell survival.
Chan W; Schaffer TB; Pomerantz JL
Mol Cell Biol; 2013 Jan; 33(2):429-43. PubMed ID: 23149938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
